EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study

Derin Karacabeyli iD, Diane Lacaille, Na Lu, Natalie McCormick iD, Hui Xie, Hyon K Choi, J Antonio Aviña-Zubieta iD

PLOS ONE · 08.08.2024 · 19 (8) · e0308533

DOI: 10.1371/journal.pone.0308533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.08.2024. Verfasst von Derin Karacabeyli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the risk of all-cause mortality and major adverse cardiovascular events (MACE) in patients with immune-mediated inflammatory diseases (IMIDs) and type 2 diabetes newly initiating glucagon-like peptide-1 receptor agonists (GLP-1-RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4is).

Methods

We performed a population-based cohort study using administrative health data from British Columbia. Patients with an IMID (i.e., rheumatoid arthritis, psoriatic disease, ankylosing spondylitis, inflammatory bowel disease, or a systemic autoimmune rheumatic disease) and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i between January 1, 2010, and December 31, 2021 were identified using ICD-9/10 codes. The primary outcome was all-cause mortality. Secondary outcomes included MACE and its components (i.e., cardiovascular death, myocardial infarction, and ischemic stroke). Cox proportional hazard regressions were used with propensity score overlap weighting. The analysis was repeated in age- and sex-matched adults without IMIDs.

Results

We identified 10,855 adults with IMIDs and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i. All-cause mortality rate was lower among initiators of GLP-1-RAs compared to initiators of DPP-4is, with a weighted hazard ratio (HR) of 0.48 (95% confidence interval [CI], 0.31–0.75) and rate difference (RD) of -9.4 (95% CI, -16.0 to -2.7) per 1000 person-years. Rate of MACE was also lower with GLP-1-RA exposure (HR 0.66 [0.50–0.88], RD -10.5 [-20.4 to -0.8]). Effect sizes were similar in adults without IMIDs.

Conclusion

In patients with IMIDs and type 2 diabetes, GLP-1-RA exposure is associated with a lower risk of all-cause mortality and MACE compared to a cardioneutral active comparator.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedAgedDipeptidyl-Peptidase IV InhibitorsAdultInflammationCohort StudiesHypoglycemic AgentsBritish ColumbiaProportional Hazards Models

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.
  • Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

ORCID-Profile: Derin Karacabeyli, Natalie McCormick, J Antonio Aviña-Zubieta

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Karacabeyli, D., Lacaille, D., Lu, N., McCormick, N., Xie, H., Choi, H. K., & Aviña-Zubieta, J. A. (2024). Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study. PLOS ONE, 19(8), e0308533. https://doi.org/10.1371/journal.pone.0308533

Vancouver

Karacabeyli D, Lacaille D, Lu N, McCormick N, Xie H, Choi HK, et al. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study. PLOS ONE. 2024;19(8):e0308533. doi:10.1371/journal.pone.0308533

BibTeX
@article{Karacabeyli2024,
  author = {Karacabeyli, Derin and Lacaille, Diane and Lu, Na and McCormick, Natalie and Xie, Hui and Choi, Hyon K and Aviña-Zubieta, J Antonio},
  title = {Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {8},
  pages = {e0308533},
  doi = {10.1371/journal.pone.0308533}
}
Kostenlos starten →